MedTrace Logo

Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT00408070 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2018-03-08

Study results available
· View outcomes & findings →

Summary

The primary objective is to determine whether the addition of bevacizumab to a regimen of carboplatin plus paclitaxel significantly improves Progression Free Survival (PFS) for patient with Stage III suboptimally cytoreduced or Stage IV ovarian, primary peritoneal or fallopian tube carcinomas.

Conditions

Interventions

DRUG

Bevacizumab

cycle 2 (6 cycles re-evaluated and follow up)

DRUG

Carboplatin

cycle #1 and continuous through entire regimen; treated every 3 weeks

DRUG

Paclitaxel

cycle #1 and continuous through entire regimen; treated every 3 weeks

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • UConn Health

    lead OTHER

Principal Investigators

  • Carolyn Runowicz, MD · UConn Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2009-08-31
Completion
2009-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00408070 on ClinicalTrials.gov